Results 151 to 160 of about 74,496 (193)

Construction of Quantitative Structure Activity Relationship (QSAR) Models to Predict Potency of Structurally Diversed Janus Kinase 2 Inhibitors. [PDF]

Molecules, 2019
Simeon S, Jongkon N.
europepmc   +1 more source

Possible interesting link between Janus kinase 2 mutation and renovascular hypertension. [PDF]

J Clin Hypertens (Greenwich), 2018
Tamura K, Haruhara K, Azushima K, Iwamoto T, Wakui H.   +4 more
europepmc   +1 more source

Successful treatment of pyoderma gangrenosum complicated by JAK2V617F mutation-positive myelofibrosis with adalimumab and systemic steroid

Journal of Cutaneous Immunology and Allergy
Kyohei Shibuta, Koremasa Hayama, Katsuhiro Miura, Hideki Fujita   +3 more
doaj   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pharmacophore and docking-based virtual screening approach for the design of new dual inhibitors of Janus kinase 1 and Janus kinase 2

SAR and QSAR in Environmental Research, 2014
Janus kinase 1 and 2, non-receptor protein tyrosine kinases, are implicated in various cancerous diseases. Involvement of these two enzymes in the pathways that stimulate cell proliferation in cancerous conditions makes them potential therapeutic targets for designing new dual-targeted agents for the treatment of cancer.
Haneesh Jasuja, Om Silakari
exaly   +3 more sources

Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F [PDF]

Journal of Cellular and Molecular Medicine, 2013
peer reviewedThe Janus kinase 2 mutant V617F occurs with high frequency in myeloproliferative neoplasms. Further mutations affecting the Janus kinase family have been discovered mostly in leukaemias and in myeloproliferative neoplasms.
Catherine Rolvering, René Eulenfeld, Guy Berchem   +2 more
exaly   +3 more sources

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

Cochrane Database of Systematic Reviews, 2015
Myelofibrosis is a bone marrow disorder characterized by excessive production of reticulin and collagen fiber deposition caused by hematological and non-hematological disorders. The prognosis of myelofibrosis is poor and treatment is mainly palliative.
Arturo J, Martí-Carvajal, Vidhu, Anand, Ivan, Solà   +2 more
openaire   +4 more sources

Downregulation of KCNQ4 by Janus Kinase 2

The Journal of Membrane Biology, 2013
Janus kinase-2 (JAK2) participates in the signaling of several hormones, growth factors and cytokines. Further stimulators of JAK2 include osmotic cell shrinkage, and the kinase activates the cell volume regulatory Na(+)/H(+) exchanger. The kinase may thus participate in cell volume regulation. Cell shrinkage is known to inhibit K(+) channels.
Hosseinzadeh, Zohreh, Sopjani, Mentor, Pakladok, Tatsiana, Bhavsar, Shefalee K., Lang, Florian   +4 more
openaire   +3 more sources

Janus kinase 2 inhibitors in myeloproliferative disorders

Expert Opinion on Investigational Drugs, 2010
JAK2 is an obligatory kinase for the proliferation and differentiation of erythroid cells and megakaryocytes thus representing a relevant therapeutic target for agents that specifically inhibit its activity particularly in myeloproliferative disorders (MPD) harboring JAK2(V617F) mutations.We discuss the physiopathology of the JAK2 signaling pathway and
Lucia E, Recchia AG, Gentile M, Bossio S, Vigna E, Mazzone C, Madeo A, Morabito L, Gigliotti V, De Stefano L, Caruso N, Servillo P, Franzese S, Bisconte MG, Gentile C, Morabito F.   +15 more
openaire   +3 more sources

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

2013
This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the clinical efficacy and safety of JAK1 and JAK2 inhibitors for treating MF generated by hematologic or non-hematologic conditions. © 2013 The Cochrane Collaboration.
Martí-Carvajal A.J., Cardona A.F., Anand V., Solà I.   +3 more
openaire   +2 more sources

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor

Blood, 2006
AbstractJAK2, a member of the Janus kinase (JAK) family of protein tyrosine kinases (PTKs), is an important intracellular mediator of cytokine signaling. Mutations of the JAK2 gene are associated with hematologic cancers, and aberrant JAK activity is also associated with a number of immune diseases, including rheumatoid arthritis.
Lucet, Isabelle S., Fantino, Emmanuelle, Styles, Michelle, Bamert, Rebecca, Patel, Onisha, Broughton, Sophie E., Walter, Mark, Burns, Christopher J., Treutlein, Herbert, Wilks, Andrew F., Rossjohn, Jamie   +10 more
openaire   +5 more sources